Keywords
Immuno-oncology therapy
Lung cancer
Abstract
Introduction: The COVID-19 pandemic raises several challenges around the treatment of non-small cell lung cancer (NSCLC) using immune checkpoint inhibitor (ICI) based therapy. ICI-therapy, also known as immuno-oncology (IO) therapy, is an upcoming approach to cancer management for several indications, and works by blocking key immune checkpoints, which enables the immune system to destroy tumour cells. Challenges include the potential risk of more severe/frequent immune-related adverse events (irAEs) in COVID-19 patients.
Aim: Explore the risks and benefits of IO-therapy for NSCLC during a COVID-19 pandemic and review current guidelines.
Case presentation: Patient X is a 70-year-old man with NSCLC who has resumed ICI-therapy after sustaining COVID-19 lung changes following his recent infection.
Method: Medical histories were taken from three ICI-patients with NSCLC. In addition, a literature review was undertaken, looking at databases including PubMed, Medline, and Scopus. Key words such as ‘covid-19’, ‘immunotherapy’ and ‘NSCLC’ were used to identify relevant literature and the literature reviewed ranged from 2015 to present day.
Results: Several studies identified poor clinical outcomes associated with IO-therapy use in lung cancer patients throughout this pandemic. However, a large body of literature suggests IO-therapy does not influence the survival of patients with COVID-19 nor the likelihood of severe complications. Thus, complete discontinuation of IO may not be necessary, though many studies did suggest that greater COVID-19 surveillance of IO patients be implemented.
Significance: Cases such as Patient X, who have COVID-19 lung changes and resume IO, are rarely seen in the literature; therefore, there is minimal guidance for similar situations. This study highlights vital areas for future research including the implications of a COVID-19 vaccine.
Conclusion: It is possible for NSCLC patients to undergo IO-therapy during the COVID-19 pandemic. However, the interaction between SARS-CoV-2 and IO-therapy is poorly understood, resultantly it is advised that a case-by-case approach is utilised and patients are involved in the uncertainty of decision-making.
References
World Health Organisation. Coronavirus disease 2019 (COVID-19) Situation Report – 94 2020 [cited 2020 Dec 06]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200423-sitrep-94-covid-19.pdf#:~:text=The%20first%20human%20cases%20of,%2C%20in%20December%202019 (accessed 05 April 2023)
World Health Organisation. COVID-19 Weekly Epidemiological Update 01 December 2020 [updated 29 November 2020; cited 2020 Dec 6]. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update---1-december-2020 (accessed 05 April 2023)
Cancer Research UK. Health Professional COVID-19 and Cancer Hub. Available from: https://www.cancerresearchuk.org/health-professional/diagnosis/hp-covid-19-and-cancer-hub#HP_COVID-191 (accessed 05 April 2023)
Assi HI, Kamphorst AO, Moukalled NM, Ramalingam SS. Immune checkpoint inhibitors in advanced non–small cell lung cancer. Cancer. 2018;124(2):248-61. Available from: https://doi.org/10.1002/cncr.31105
Wecker L. Brody’s Human Pharmacology. 6 ed. Philadelphia, PA: Elsevier; 2019.
Varricchi G. Galdierro MR, Tocchetti C.G. Cardiac toxicity of immune checkpoint inhibitors: cardio-oncology meets immunology. Circulation. 2017;136(21):1989-1992. Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.029626
Zhou G-W, Xiong Y, Chen S, Xia F, Li Q, Hu J. Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials. Medicine. 2016;95(35):e4611.
Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017: 28(suppl_4):iv119-iv142. Available from: https://doi.org/10.1093/annonc/mdx225
Suresh K, Naidoo J, Lin CT, Danoff S. Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities. Chest. 2018;154(6):1416-23. Available from: https://doi.org/10.1016/j.chest.2018.08.1048
Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375-91. Available from: https://doi.org/10.1093/annonc/mdv383
Gambichler T, Reuther J, Scheel CH, Becker JC. On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19. J Immunother Cancer. 2020;8(2). Available from: https://doi.org/10.1136/jitc-2020-001145
Fraser E. Long term respiratory complications of covid-19. BMJ. 2020;370:m3001. Available from: https://doi.org/10.1136/bmj.m3001
John Hopkins Medicine. What Coronavirus does to the lungs 2020 [Available from: https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/what-coronavirus-does-to-the-lungs (accessed 05 April 2023)
Tabary M, Khanmohammadi S, Araghi F, Dadkhahfar S, Tavangar SM. Pathologic features of COVID-19: A concise review. Pathol Res Pract. 2020;216(9):153097. Available from: https://doi.org/10.1016/j.prp.2020.153097
Jain A. COVID-19 and lung pathology. Indian J Pathol Microbiol. 2020;63(2):171-2. Available from: https://doi.org/10.4103/IJPM.IJPM_280_20
Hu Q, Guan H, Sun Z, et al. Early CT features and temporal lung changes in COVID-19 pneumonia in Wuhan, China. Eur J Radiol. 2020;128:109017. Available from: https://doi.org/10.1016/j.ejrad.2020.109017
NICE. COVID-19 rapid guideline: delivery of systemic anticancer treatments 2020 [updated Nov 9, 2020; cited 2020 Dec 15]. Available from: https://www.nice.org.uk/guidance/ng161/chapter/3-Patients-known-or-suspected-to-have-COVID19 (accessed 05 April 2023)
Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894-901. Available from: https://doi.org/10.1016/j.annonc.2020.03.296
Di Noia V, D’Aveni A, Squadroni M, Beretta GD, Ceresoli GL. Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire? Lung Cancer. 2020;145:208-10. Available from: https://doi.org/10.1016/j.lungcan.2020.05.006
Remon J, Mezquita L, Corral J, Vilariño N, Reguart N. Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. J Thorac Dis. 2018;10(Suppl 13):S1516-s1533. Available from: https://doi.org/10.21037/jtd.2017.12.52
Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-81. Available from: https://doi.org/10.1016/S2213-2600(20)30079-5
Russano M, Citarella F, Napolitano A, et al. COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management. Expert Opin Biol Ther. 2020;20(9):959-64. Available from: https://doi.org/10.1080/14712598.2020.1789097
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect. 2020;80(6):607-13. Available from: https://doi.org/10.1016/j.jinf.2020.03.037